CN1586486A - Cefpodoxime proxetil soft capsule preparation and its preparing method - Google Patents
Cefpodoxime proxetil soft capsule preparation and its preparing method Download PDFInfo
- Publication number
- CN1586486A CN1586486A CN 200410068904 CN200410068904A CN1586486A CN 1586486 A CN1586486 A CN 1586486A CN 200410068904 CN200410068904 CN 200410068904 CN 200410068904 A CN200410068904 A CN 200410068904A CN 1586486 A CN1586486 A CN 1586486A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- cefpodoxime proxetil
- capsule
- cefpodoxime
- proxetil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title claims abstract description 34
- 229960004797 cefpodoxime proxetil Drugs 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000007901 soft capsule Substances 0.000 title claims description 23
- 238000000034 method Methods 0.000 title description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 235000011187 glycerol Nutrition 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 6
- 108010010803 Gelatin Proteins 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 229920000159 gelatin Polymers 0.000 claims abstract description 5
- 235000019322 gelatine Nutrition 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000008118 PEG 6000 Substances 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000248349 Citrus limon Species 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000007872 degassing Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 239000002775 capsule Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 description 11
- 238000001556 precipitation Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229960005090 cefpodoxime Drugs 0.000 description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses one kind of soft cefpodoxime proxetil capsule and its preparation process. The medicine consists of medicine liquid and capsule shell, the medicine liquid contains cefpodoxime proxetil, matrix and stabilizer, and the capsule shell contains gelatin, glycerin, water, preservative and light screening agent. Compared with available cefpodoxime proxetil preparations, the present invention is even suitable for children and other people incapable of taking care of himself to take and has the advantages of high bioavailability, high stability, accurate content, etc.
Description
Technical field
The present invention relates to soft capsule preparation of Cefpodoxime Proxetil and preparation method thereof, belong to the technical field of medicine and preparation thereof.
Technical background
Cefpodoxime Proxetil (Cefpodoxime proxetil) is that Japan three common (Sankyo) Co., Ltd. succeeded in developing and produced the oral efficient third generation cephalosporin of listing in 1989.Cefpodoxime Proxetil is the precursor of cefpodoxime (Cefpodoxime), demonstrates good antibacterial activity after the absorption, and its antibacterial activity is that it suppresses the synthetic of bacteria cell wall, and is highly stable to beta-lactamase.Has a broad antifungal spectrum comprises traditional pathogenic bacteria of drug-resistant, multiple gram positive bacteria and gram negative bacteria all there is very strong antibacterial activity, especially staphylococcus, Streptococcus etc. there is high activity, the significant advantage that is better than other third generation cephalosporin is provided.Also has Synergistic biocidal effect with the organism infection defensive enginery.Since Cefpodoxime Proxetil have broad-spectrum antiseptic, anti-enzyme, oral effectively, long half time and take the few advantage of number of times, not only solved the problem of bacterial resistance preferably, and kept the excellent safety of Beta-lactam medicine, be fit to very much the child and use.But mostly be the dosage form that suitable adult such as Cefpodoxime Proxetil sheet, Cefpodoxime Proxetil capsule, Cefpodoxime proxetil suspension uses at present clinically, do not have the children special-purpose dosage form.And the child has a lot of particularitys at physiology with comparing with the adult psychologically, each phylogeny of health is unsound, swallow is poor, that takes care of oneself is indifferent, poor to drug compliance, originally should be different to some extent in the medication, therefore press for the dosage form of a kind of suitable children taking of exploitation, make child's clinical application safer, convenient, economical.Same for the relatively poor patient of similar self care ability with the child, gerontal patient for example, special populations such as dementia patient also are badly in need of a kind of suitable pharmaceutical dosage form clinically.
Summary of the invention
Purpose of the present invention is exactly that dosage form at existing Cefpodoxime Proxetil is applicable to that the adult takes more, provides a kind of child and the patient that can't take care of oneself takes safety, Cefpodoxime proxetil soft capsule dosage form and preparation technology thereof easily.The present invention easily packs, transports, preserves, compares with tablet, without compression process, so disintegrate and rate of dispersion are fast, the higher advantage of bioavailability is arranged, content accurately, good uniformity, good looking appearance, taste and abnormal smells from the patient zest are not strong, easily be accepted, especially make special-shaped soft capsule and also can be called the capsule-type drop, splash in the mouth after can puncturing, it is very convenient to take, the patient's use that very is fit to the child and can't take care of oneself.
The present invention is made of medicinal liquid and softgel shell two large divisions, medicinal liquid by weight every contain the 10-160mg Cefpodoxime Proxetil and contain substrate 40-600mg, stabilizing agent 0.4-500mg, the gelatin that contains 10 parts of weight in the softgel shell, the glycerol of 3-6 part weight, the water of 10 parts of weight and antiseptic, lucifuge agent.
The present invention can contain in liquid polyethylene glycol, glycerol and the vegetable oil one or more as substrate; Contain in ethyl cellulose, PEG6000, Cera Flava, hydroxypropyl cellulose, single-stearic acid aluminum, lecithin, the Arlacel-80 one or more as stabilizing agent; Contain in ethyl hydroxybenzoate, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, the butyl p-hydroxybenzoate one or more as antiseptic; In ferrum oxide, curcumin, lemon yellow, the titanium dioxide one or more are as the lucifuge agent.Can also add any pharmaceutically useful adjuvant in the soft capsule of the present invention, as long as the adjuvant safety, the avirulence that add, do not destroy effect of the present invention on the contrary.
The present invention is an oral administered dosage form; in this dosage form; Cefpodoxime Proxetil is in the suspension state; can overcome the shortcoming of existing dosage form; bioavailability significantly improves, and has added the lucifuge agent in the capsule material of soft capsule, can block the influence of daylight to medicine; thereby the protection Cefpodoxime Proxetil is not subjected to photodissociation, has improved the stability of this product greatly.And satisfy such dosage form and rationalize standard aspect stable at outward appearance, hardness, disintegration etc.Said preparation guaranteeing under the suitable prerequisite of principal agent dosage, by selecting adjuvant and formulation method for use, Cefpodoxime Proxetil made suspension be wrapped in and make soft capsule in the rubber, help medicine oral, absorb, reach high bioavailability.Clinical a kind of renewal, the better dosage form selection of providing also is provided simultaneously.
The present invention is owing to be soft capsule, and medicine is hedged off from the outer world in the shell, can be moistureproof, anti-oxidation, lucifuge, medicine stability be good.Done following accelerated test for proving these characteristics.
Accelerated test
| Time (moon) | Character | Related substance (%) | Content % | Disintegration (minute) |
| ????0 | Bright and clean crack-free content does not have precipitation | ????0.23 | ????100 | ????10.5 |
| ????1 | Bright and clean crack-free content does not have precipitation | ????0.31 | ????99.4 | ????10.3 |
| ????2 | Bright and clean crack-free content does not have precipitation | ????0.52 | ????98.9 | ????10.9 |
| ????3 | Bright and clean crack-free content does not have precipitation | ????0.56 | ????98.7 | ????11.1 |
| ????6 | Bright and clean crack-free content does not have precipitation | ????0.52 | ????99.0 | ????11.2 |
Specific embodiments
The detailed component of the present invention is provided by the following example, but protection scope of the present invention is not limited to this.
Embodiment 1
In 1kg gelatin, 350g glycerol, 1kg water, an amount of pigment, putting of 2.5g ethyl hydroxybenzoate glue jar, again with about this mixture heated to 70～80 ℃, mix homogeneously, evacuation, filtration, insulation is left standstill, and is stand-by.Get the PEG6000 of 3g and the PEG400 of 257g, heat fused, the Cefpodoxime Proxetil that adds 40g more fully mixes in blender, measures content, and is stand-by.In the soft capsule maker, after the compacting, drop put in the forming machine finalize the design.After the washing, drop about 30 ℃ dry 12 hours.
According to the technology of embodiment 1, below can change detailed component.
Embodiment 2
Group component (g)
Cefpodoxime Proxetil 40
Hydroxypropyl cellulose 15
Vegetable oil 245
Embodiment 3
Group component (g)
Cefpodoxime Proxetil 40
Cera Flava 9
Vegetable oil 251
Embodiment 4
Group component (g)
Cefpodoxime Proxetil 45
Aluminum monostearate 6
Arlacel-80 30
Vegetable oil 219
Although described the present invention by specific embodiment, some is revised and equivalence is obvious for the technical staff who is proficient in this field, and these variations are believed to comprise within the scope of the present invention.
Claims (9)
1, a kind of Cefpodoxime proxetil soft capsule preparation, Cefpodoxime Proxetil is to be sealed in the soft capsule with the suspension state, it is characterized in that medicinal liquid by weight every contain 10-160mg and contain substrate 40-600mg, stabilizing agent 0.4-50mg, the gelatin that contains 10 parts of weight in the softgel shell, the glycerol of 3-6 part weight, the water of 10 parts of weight and antiseptic, pigment.
2,, it is characterized in that can be made into two kinds of forms of common soft capsule and capsule-type drop as the said Cefpodoxime proxetil soft capsule of claim 1.
3,, it is characterized in that the capsule-type drop can be made into Pear-Shaped, special-shaped soft capsule such as ellipse as the said Cefpodoxime proxetil soft capsule of claim 2.
4,, it is characterized in that substrate is one or more in liquid polyethylene glycol, glycerol and the vegetable oil as the said Cefpodoxime proxetil soft capsule of claim 1;
5,, it is characterized in that stabilizing agent is one or more in hydroxypropyl cellulose, ethyl cellulose, single-stearic acid aluminum, PEG6000, Cera Flava, lecithin, the Arlacel-80 as the said Cefpodoxime proxetil soft capsule of claim 1.
6,, it is characterized in that antiseptic is one or more in ethyl hydroxybenzoate, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, the butyl p-hydroxybenzoate as the said Cefpodoxime proxetil soft capsule of claim 1;
7,, it is characterized in that the lucifuge agent is one or more in ferrum oxide, curcumin, lemon yellow, the titanium dioxide as the said Cefpodoxime proxetil soft capsule of claim 1.
8, as the said Cefpodoxime proxetil soft capsule of claim 1, the preparation technology who it is characterized in that it may further comprise the steps: in gelatin, glycerol, water, antiseptic, putting of lucifuge agent glue jar, again with about this mixture heated to 70～80 ℃, mix homogeneously, evacuation, filter, insulation is left standstill, and is stand-by; Get substrate, the stabilizing agent of recipe quantity, heat fused, the Cefpodoxime Proxetil that adds recipe quantity more fully mixes in blender, and degassing back is put drop in the forming machine and to be finalized the design, after the washing drying, promptly in the soft capsule maker after the compacting.
9, as the said Cefpodoxime proxetil soft capsule of claim 1, the clinical infection that is widely used in responsive microbial department of otorhinolaryngology infection, respiratory system infection, urinary system infection, skin soft tissue etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410068904 CN1586486A (en) | 2004-07-12 | 2004-07-12 | Cefpodoxime proxetil soft capsule preparation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410068904 CN1586486A (en) | 2004-07-12 | 2004-07-12 | Cefpodoxime proxetil soft capsule preparation and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1586486A true CN1586486A (en) | 2005-03-02 |
Family
ID=34604200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410068904 Pending CN1586486A (en) | 2004-07-12 | 2004-07-12 | Cefpodoxime proxetil soft capsule preparation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1586486A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441173C (en) * | 2005-11-25 | 2008-12-10 | 石药集团欧意药业有限公司 | Agastachel patchoule summer heat dispelling soft capsule and its preparation method |
| CN100544707C (en) * | 2005-12-14 | 2009-09-30 | 王殿华 | panacea grass soft capsule and production method thereof |
| CN103263399A (en) * | 2013-06-06 | 2013-08-28 | 南京正宽医药科技有限公司 | Cefradine capsules and preparation method thereof |
| CN103462928A (en) * | 2013-09-04 | 2013-12-25 | 南京正亮医药科技有限公司 | Cefalexin capsules and preparation method thereof |
-
2004
- 2004-07-12 CN CN 200410068904 patent/CN1586486A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441173C (en) * | 2005-11-25 | 2008-12-10 | 石药集团欧意药业有限公司 | Agastachel patchoule summer heat dispelling soft capsule and its preparation method |
| CN100544707C (en) * | 2005-12-14 | 2009-09-30 | 王殿华 | panacea grass soft capsule and production method thereof |
| CN103263399A (en) * | 2013-06-06 | 2013-08-28 | 南京正宽医药科技有限公司 | Cefradine capsules and preparation method thereof |
| CN103263399B (en) * | 2013-06-06 | 2015-07-22 | 南京正宽医药科技有限公司 | Cefradine capsules and preparation method thereof |
| CN103462928A (en) * | 2013-09-04 | 2013-12-25 | 南京正亮医药科技有限公司 | Cefalexin capsules and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69924381T2 (en) | EASILY FALLING SOLID PREPARATION | |
| CN104739921B (en) | A kind of formula lozenge for relieving visual fatigue and preparation method thereof | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN104622870A (en) | Gluconic acid chlorhexidine composite gargle and preparation method thereof | |
| CN107028876B (en) | Polyethylene glycol electrolyte oral liquid and preparation method thereof | |
| CN103417562B (en) | Nifuratel-nysfungin vaginal soft capsule and preparation method thereof | |
| CN1586486A (en) | Cefpodoxime proxetil soft capsule preparation and its preparing method | |
| CN105832763A (en) | Medicine composition containing sodium L-ascorbate and preparing method of medicine composition | |
| CN107522717A (en) | A kind of lavo-ofloxacin hydrochloride crystal and combinations thereof | |
| RU2605271C1 (en) | Granules with extracts of cranberries, red bilberry madder antidiuretic, antispasmodic and litholytic action | |
| CN1586484A (en) | Dipyridamole soft capsule preparation and its preparing method | |
| CN101049485A (en) | Mulberry - ginger soft capsule for treating common cold, and preparation method | |
| CN100386071C (en) | Medicine for treating cough and chronic bronchitis | |
| CN101229149B (en) | Meclofenoxate hydrochloride stomach-floating sustained release capsule and preparing method thereof | |
| CN102552210B (en) | Entecavir capsule and preparation method thereof | |
| CN104546697B (en) | A kind of Dexibuprofen injection pharmaceutical composition and preparation method thereof | |
| CN103301075A (en) | Suspension granules for cefixime composition and preparation method thereof | |
| CN102784121A (en) | Levofloxacin composition freeze-dried orally disintegrating tablets and preparation method thereof | |
| CN105726491A (en) | Polyhexamethylene guanidine medicine for treating stomach disease and preparation method and application thereof | |
| CN100367938C (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| DE69911427T2 (en) | COMPRESSED COMPOSITIONS WITH CLEANED XANTHAN GUM | |
| CN116531326B (en) | Oral emulsion of apremilast and preparation method thereof | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN101427999B (en) | Frusemide oral solution and method of producing the same | |
| KR101458670B1 (en) | Pharmaceutical composition comprising branched chain amino acids as active ingredients and the preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |